In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Catabasis Pharmaceuticals (CATB), with a price target of $20. The company’s shares opened today at $7.05.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -7.5% and a 38.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on Catabasis Pharmaceuticals is a Moderate Buy with an average price target of $46, a 552.5% upside from current levels. In a report issued on March 14, Oppenheimer also reiterated a Buy rating on the stock with a $72 price target.
See today’s analyst top recommended stocks >>
Based on Catabasis Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $6.06 million. In comparison, last year the company had a GAAP net loss of $5.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy.
